



# Un altro recettore dell'Epo!





Famiglia dei recettori  
delle citochine




Legame del ligando  
↓  
Dimerizzazione  
↓  
Attivazione del  
recettore

# EPO targets many cell types and tissues

A



# Multifaceted effects and targets of EPO




EPO targets many cell types and tissues, including erythroid cells and their progenitors, tumor cells, and a variety of other nonerythroid cells and tissues

EPO signals in erythroid cells via EPOR-EPOR homodimers

and in nonerythroid cells via EPOR-CD131 heterodimers

# Mutazioni nella Pathway oxygen sensing

# Mutazioni nella Pathway oxygen sensing



# Policitemia di Chuvash

Ang et al. Nature Genetics 2002

- Policitemia autosomica recessiva trovata in Russia

**Table 1 • Biochemical parameters in Chuvash polycythemia**


	Individuals with Chuvash polycythemia (n = 20)	Unaffected relatives (n = 51)	P
Erythropoietin (mIU ml <sup>-1</sup> )	61.9 ± 12.8	6.4 ± 6.9	0.001

Sequenziamento gene von Hippel Lindau (VHL) →  
C/T transition, Arg/Trp200 (Pazienti omozigoti)

# Disruption of oxygen homeostasis underlies congenital Chuvash polycythemia

Sonny O. Ang

Nature genetics 2002, volume 32 no. 4 pp 614 - 621



20% O<sub>2</sub>:


- Livelli di proteina VHL normali in mutato e Wt
- Livelli di HIF1α maggiori nei soggetti affetti

Western blot, 5 pazienti + 5 controlli

# Disruption of oxygen homeostasis underlies congenital Chuvash polycythemia

Sonny O. Ang

Nature genetics 2002, volume 32 no. 4 pp 614 - 621



V= controllo (Wild type)

H= eterozigote


P1= paziente (omozigote)

La forma ubiquitinizzata è meno presente nelle cellule del paziente

Mutazione Arg200Trp:


- Ridotta ubiquitinizzazione di HIF1α
- Aumentata espressione del gene Epo → policitemia

# Response to hypoxia - chronic adaptation




# VHL mutation Hypoxia, angiogenesis, and metabolism in the hereditary kidney cancers

**A** Normoxic cellular metabolism



**B** VHL-deficient RCC metabolic reprogramming by HIF  
renal carcinoma cells (RCC)




VHL mutation


# Adattamento cronico all'ipossia.....

Figure 3: Hypoxia and angiogenesis,in the hereditary kidney cancers

**A WT**



**B VHL mutant**



vascular abnormalities


1 ectopic expression of smooth muscle  $\alpha$ -actin ( $\alpha$ -SMA; green) by vascular pericytes

2 elevated vessel density

3 development of arteriovenous shunts

Mutazioni nella Pathway oxygen sensing: **PHD**

Increased survival, proliferation, and differentiation of erythroid progenitor cells



Mutazioni nella Pathway oxygen sensing: **HIF**

**a**


Location	Possible Role	Primary Tissue (Subtype)	Associated Histology
<b>HIF-2<math>\alpha</math></b>			
K18E		Stomach	Adenocarcinoma
A23V		Endometrium	Endometrioid carcinoma
V47M		Central nervous system (brain)	Glioma
F98L		Large intestine (colon)	Adenocarcinoma
R166L		Kidney	Clear cell renal cell carcinoma
I223M		Lung	Adenocarcinoma
H248N		Large intestine (colon)	Adenocarcinoma
R275H		Cervix	Squamous cell carcinoma
A277P		Lung	Squamous cell carcinoma
E279V		Liver	Hepatocellular carcinoma
<b>HIF-1<math>\alpha</math></b>			
K19Q		Endometrium	Endometrioid carcinoma
R30Q		Skin	Malignant melanoma
L54I		Kidney	Clear cell renal cell carcinoma
V116E		Kidney	Clear cell renal cell carcinoma
M120T		Large intestine (colon)	Adenocarcinoma
M171I		Kidney	Clear cell renal cell carcinoma
M250I		Lung	Adenocarcinoma
L262S		Skin	Malignant melanoma
V341I		Endometrium	Endometrioid carcinoma

cancer-related mutations in HIF-2 $\alpha$  and HIF-1 $\alpha$


Genere: carcinoma endometrio

## HIF-1 $\alpha$

K19Q	bHLH $\alpha$ 1	DNA interaction
R30Q	bHLH $\alpha$ 1	DNA interaction
L54I	bHLH $\alpha$ 1- $\alpha$ 2 loop	Interface 6 (bHLH/PAS-A)
V116E	PAS-A C $\alpha$	Internal stability
M120T	PAS-A C $\alpha$	Internal stability
M171I	PAS-A G $\beta$	Internal stability
M250I	PAS-B A $\beta$ -B $\beta$ loop	Internal stability
L262S	PAS-B C $\alpha$	Internal stability
V341I	PAS-B I $\beta$	Internal stability



cancer-related mutations in HIF-1 $\alpha$




K19Q



HIF-1 $\alpha$ :ARNT:DNA

**a**

	Location	Possible Role
<b>HIF-2<math>\alpha</math></b>		
K18E	bHLH $\alpha$ 1	DNA interaction
A23V	bHLH $\alpha$ 1	DNA interaction
V47M	bHLH $\alpha$ 1- $\alpha$ 2 loop	Interface 6 (bHLH/PAS-A)
F98L	PAS-A A $\beta$	Internal stability
R166L	PAS-A G $\beta$	Internal stability
I223M	PAS-A I $\beta$	Interface 2 (PAS-A/PAS-A)
H248N	PAS-B A $\beta$	Internal stability
R275H	PAS-B D $\alpha$ -E $\alpha$ loop	Internal stability
A277P	PAS-B E $\alpha$	Internal stability
E279V	PAS-B E $\alpha$	Internal stability




cancer-related mutations in HIF-2 $\alpha$




Mutazioni nella Pathway oxygen sensing:  
**Gain of Function «GoF» EPOR**


Increased survival, proliferation, and differentiation of erythroid progenitor cells



# Trasduzione del segnale continua



Dimerizzazione di EpoR  
Fosforilazione di JAK e  
attivazione di JAK chinasi




Dimerizzazione di EpoR  
Fosforilazione di JAK e  
attivazione di JAK chinasi



Mutated Receptor  
Mutated Jak...

# Chronic Kidney Disease

## Normal Kidney



## CKD



**Anemia**


Inadeguata produzione endogena  
(patologia renale)




Carenza di globuli rossi




Anemia



# Effect of erythropoietin (EPO) on the blood transcriptome after cardiac arrest



## Effects of erythropoietin (EPO) on the transcriptome after cardiac arrest



# Trattamento dell'anemia

## Epo ricombinante (rHuEPO)


Produzione su larga scala di Epo umana  
ricombinante

rHuEPO

34000 Da


prodotta in cellule mammarie in cui è stato  
introdotto il gene dell'Epo

Epo contains **one** O-linked and **three** N-linked carbohydrate chains, each having 2–4 branches that often end in a negatively charged sialic acid.



Ser126 is the site for O-linked carbohydrate.

Steve Elliott et al. J. Biol. Chem. 2004;279:16854-16862




**Carbohydrate chains are not required for receptor binding in vitro or stimulation of growth of EpoR-expressing cultured cells**

**required for the in vivo bioactivity**

These carbohydrate chains are not required for receptor binding in vitro or stimulation of growth of EpoR-expressing cultured cells but are **required for the in vivo bioactivity**

**Introduced (recombinant) consensus sequences in the rHuEPO amino acid backbone.**

**introduced N-linked consensus sequences**




- more than half the molecules contained additional carbohydrate

Steve Elliott et al. J. Biol. Chem. 2004;279:16854-16862

- 
- 
- 2 additional N-linked glycosylation sites
- Novel Erythropoiesis Stimulating Protein (NESP)
  - Aumentato contenuto di carboidrati conferisce un aumento dell'emivita



## Net binding of $^{125}\text{I}$ -Epo or $^{125}\text{I}$ -NESP with UT-7/Epo cells at 37 °C.



Cells were collected and rapidly separated from the medium after the indicated time

Cell-associated radioactivity was measured.


### Net binding of $^{125}\text{I}$ -Epo or $^{125}\text{I}$ -NESP with UT-7/Epo cells at 37 °C.



## • Novel Erythropoiesis Stimulating Protein (NESP)

- Epo isoforms with higher sialic acid content have
  - a lower affinity for EpoR
  - a longer serum half-life?


## Degradation and endocytosis of Epo and NESP by Ba/F3-huEpoR cells.




proteins precipitated by trichloroacetic acid from the **media** of the cultures were separated by SDS-PAGE and analyzed by autoradiography

## Degradation and endocytosis of Epo and NESP by Ba/F3-huEpoR cells.

A.



B.



# Novel Erythropoiesis Stimulating Protein (NESP)

- Epo isoforms with higher sialic acid content have
    - a lower affinity for EpoR
    - a longer serum half-life
- are more effective for stimulating the production of red blood cells *in vivo*.

Somministrazione meno frequente